66
Views
3
CrossRef citations to date
0
Altmetric
Original Research

Risk of diarrhea in patients with type 2 diabetes mellitus treated with sitagliptin: a meta-analysis of 30 randomized clinical trials

, , , &
Pages 2283-2294 | Published online: 11 Nov 2014

Abstract

Background

Sitagliptin is an important drug used for diabetes treatment and is used as a monotherapy in diabetic patients. However, there are also reported cases of diarrhea with sitagliptin use. Unfortunately, data concerning the relationship of diarrhea with sitagliptin use in various conditions have yet to be identified. Therefore, the overall incidence and risk of diarrhea with sitagliptin use have not been well defined.

Methods

We conducted searches on Embase, PubMed, and the Cochrane Library databases for relevant randomized controlled trials. Registered relevant trials at the clinical trials registration website were also searched. Statistical analyses were conducted to calculate the overall incidence, odds ratios, and 95% confidence intervals (CI) by using either random-effects or fixed-effect models according to the heterogeneity of the included studies.

Results

A total of 8,891 subjects with diabetes from 30 randomized clinical trials were included in the meta-analysis. The overall incidence of sitagliptin-associated diarrhea was 4.48% (95% CI: 3.59%–5.58%). Compared with the controls, the use of sitagliptin was not associated with a significantly increased risk of diarrhea with an odds ratio of 1.10 (95% CI: 0.78%–1.55%; P=0.58). No evidence of publication bias was observed.

Conclusion

Our study has shown that there is no difference in diarrhea risk between sitagliptin and controlled therapies. Moreover, sitagliptin is not a medicine that potentially increases the risk of diabetic diarrhea. More studies are recommended to further investigate this association.

Introduction

Diabetes mellitus (DM) is one of the most prevalent worldwide endocrine system diseases. According to a report by Wild et alCitation1 there were 171 million patients diagnosed with DM worldwide in the year 2000, and this number is predicted to increase to 366 million by the year 2030. Characteristics of DM include hyperglycemia and disturbances in carbohydrate levels and, typically, there is also insulin deficiency and insulin resistance.Citation2 In clinical practice, type 2 diabetes mellitus (T2DM) is more common,Citation3 and the main monitoring indices of T2DM are glycosylated hemoglobin (HbA1c) levels and fasting blood glucose (FBG) levels.Citation4 Thus, the main strategy for T2DM therapy is to control the levels of HbA1c and FBG. At present, oral hypoglycemic agents (OHAs) are the most commonly used treatment for T2DM. Some of these OHAs include sulfonylurea, the biguanide class of drugs, dipeptidyl peptidase-4 (DPP-4) inhibitors, and glucagon-like peptide-1 (GLP-1) agonists.Citation5

Sitagliptin is an important OHA used for T2DM. It was the first DPP-4 inhibitor to be used in clinical practice in 2006.Citation6 DPP-4 is an enzyme located in the endothelium and has a high affinity toward GLP-1 as a substrate.Citation7 Sitagliptin is a highly selective DPP-4 inhibitor that can increase concentrations of intact plasma GLP-1 and lower or normalize blood glucose levels in T2DM patients.Citation8

In monotherapy of T2DM patients, sitagliptin improved HbA1c, FBG, and postprandial glucose with doses of 100 mg and 200 mg once daily.Citation9 FBG was dose-dependently reduced by 17.1 mg/dL (100 mg) and 21.3 mg/dL (200 mg); HbA1c was also reduced by 0.79% and 0.94%, respectively. In another monotherapy study,Citation10 sitagliptin also improved glycemic parameters, including HbA1c and FBG. There are also reports of diarrhea with sitagliptin as monotherapy.Citation9,Citation11 However, data concerning diarrhea with sitagliptin use in different clinical trials have not been evaluated, and the overall incidence and risk of diarrhea with sitagliptin use have not been well defined. As diarrhea could lead to a discontinuation of sitagliptin use and could be fatal in many instances, it is important to fully recognize the risk of diarrhea induced by sitagliptin. Therefore, we conducted this systematic review and meta-analysis to investigate the incidence and risk of diarrhea in T2DM patients treated with sitagliptin.

Methods

Search strategy and study selection

We searched Embase from the dates of 1974 through 2014, PubMed from 1967 through 2014, and the Cochrane Library electronic databases. Specifically, we used the following search terms treated as Medical Subject Headings (MeSH) terms or free text: “diabetes”, “diabetes mellitus”, “type 2 diabetes”, or “noninsulin-dependent diabetes mellitus”; “sitagliptin”; and “randomized controlled trials”, “clinical trials”, “controlled clinical trials”, “clinical trial as topic”, or “randomized controlled trial as topic”. Additionally, we searched the clinical trial registration website (ClinicalTrials.gov) to obtain information on the registered clinical trials. Detailed search strategies are shown in . Clinical trials that reported the occurrence of diarrhea with sitagliptin use in adult T2DM patients were eligible for inclusion.

Other inclusion criteria included: 1) the diagnosis of T2DM based on either the American Diabetes Association criteriaCitation12 or the World Health Organization criteria,Citation13 2) patients who were assigned to treatment with sitagliptin, and 3) treatment with sitagliptin for a minimum duration of 12 weeks. This duration was chosen based on the fact that a study of this duration could provide relevant information on diarrhea.

Data extraction and quality assessment

Data extraction was conducted by two independent investigators (ZQW and HDS), and studies were retrieved for further consideration if judged pertinent by one or two reviewers. Discrepancies were identified and resolved by consensus or, as needed, by a third investigator (WBH) and confirmed by consensus. When there were multiple reports from the same trial, the most complete and/or most recently reported data were chosen.

For each study, the following information was extracted: first author’s name, year of publication, the Clinical Trials Registry number (No NCT), treatment arm, treatment duration, mean age, number of patients in the treatment and control groups, adverse outcomes (diarrhea), change from baseline of HbA1c and FBG in treatment and control groups, and dosage of sitagliptin. All of the randomized controlled trials (RCTs) included in this review had their quality assessed using the Jadad criteria.Citation14 Scores ranged from 0 to 5, with a high score indicating a high-quality study.

Data analysis

The number of patients with diarrhea in the sitagliptin group and the total number of patients receiving sitagliptin were extracted from the selected trials to calculate the incidence of diarrhea. For each study, the proportion of patients with diarrhea and the 95% confidence interval (CI) were derived. The odds ratio (OR) of diarrhea was calculated only with those assigned to the control group in the same trial. We used the Peto method to calculate the OR and the 95% CI because this method provides the best CI coverage and it was more powerful and relatively less biased when dealing with low event rates.Citation15 Heterogeneity was assessed by using the Q statistic and I 2 tests among trials.Citation16 Heterogeneity was considered statistically significant when Pheterogeneity<0.1 or I 2>40%. If heterogeneity existed, the data were analyzed using a random-effects model; if heterogeneity did not exist, a fixed-effects model was used. A statistical test with a P-value <0.05 was considered significant. The presence of publication bias was evaluated by using the Begg’s and Egger’s tests.Citation11,Citation17

All data analyses were performed by using Stata software, version 12.0 (Stata Corporation, College Station, TX, USA) and R software, version 3.0.3 (The R foundation for statistical computing, http://www.r-project.org).Citation18

Results

Search results

A total of 1,761 articles and 94 clinical trials were identified initially through our search. After reviewing each study, 1,728 studies were excluded (). The remaining 30 studies, with 8,891 subjects, which met our inclusion criteria, were included in our analyses. The basic characteristics of the trials included in the meta-analysis are summarized in . The quality of the 30 clinical trials was high. Seven of them had Jadad scores of 5,Citation19Citation25 which described the methods of randomization and blinding appropriately and provided the number of patients who withdrew and dropped from the trials. Thirteen clinical trials had Jadad scores of 4.Citation9,Citation10,Citation26Citation36 This lower score was due to the fact that the researchers did not describe the methods of randomization or blinding appropriately. Ten studies had Jadad scores of 3, which included seven articlesCitation37Citation43 and three clinical trials from the clinical trial registration website. We performed this meta-analysis in accordance with the guidelines of the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) StatementCitation44 ().

Table 1 Baseline characteristics of 30 included trials in the meta-analysis (n=8,891)

Figure 1 Flow chart demonstrating the process of study selection.

Abbreviation: OHA, oral hypoglycemic agent.
Figure 1 Flow chart demonstrating the process of study selection.

Incidence of diarrhea and subgroup analysis

A total of 5,362 patients who were treated with sitagliptin monotherapy were available for analysis. The incidence of diarrhea ranged from 0% to 10.8%, and the highest incidence occurred in the trials of patients treated with 50 mg of sitagliptin once daily during a 54-week period.Citation20 No events of diarrhea were reported in the two trials.Citation39,Citation40 Based on data from 5,362 patients, the overall incidence of diarrhea was 4.48% (95% CI: 3.59%–5.58%; ) according to the random-effects model.

Figure 2 Incidence of diarrhea associated with sitagliptin.

Note: aProportion represents diarrhea as a proportion of the different types of reactions to sitagliptin.
Abbreviations: CI, confidence interval; W, weight.
Figure 2 Incidence of diarrhea associated with sitagliptin.

The incidence of diarrhea might be different due to the duration and dosage of sitagliptin treatment; therefore, we performed a subgroup analysis according to the duration and dosage of sitagliptin administration. If the dosage of sitagliptin was ≥100 mg, the incidence of diarrhea for treatment times <30 weeks (3.83%, 95% CI: 3.02%–4.84%; ) was lower than that for treatment times >30 weeks (5.41%, 95% CI: 3.62%–8.01%; ). However, if the dosage of sitagliptin was <100 mg, the incidence of diarrhea did not significantly vary between groups with treatment times <30 weeks (4.81%, 95% CI: 1.68%–12.97%; ) and treatment times >30 weeks (4.83%, 95% CI: 2.83%–8.15%; ). Through our subgroup analysis, our results suggest that under the conditions of high sitagliptin dosage (≥100 mg), a long treatment time (>30 weeks) might increase the incidence of diarrhea, but low sitagliptin dosages (<100 mg) showed no significant variation between the groups of different treatment times.

Figure 3 Incidence and risk of diarrhea with sitagliptin use based on subgroups.

Note: aProportion represents diarrhea as a proportion of the different types of reactions to sitagliptin.
Abbreviations: CI, confidence interval; W, weight.
Figure 3 Incidence and risk of diarrhea with sitagliptin use based on subgroups.

ORs of diarrhea

To investigate the specific contribution of sitagliptin to the incidence of diarrhea and exclude the influence of confounding factors such as food, the disease itself, and the history of other therapeutic interventions, we determined the ORs of diarrhea between sitagliptin and placebo groups.Citation9,Citation19,Citation24,Citation26,Citation27,Citation29,Citation32,Citation33,Citation37Citation39,Citation42,Citation45 The pooled ORs of diarrhea showed that there were no differences in diarrhea risk between treatments with sitagliptin and placebo with an OR of 1.10 (95% CI: 0.78–1.55; P=0.58; ), according to a fixed-effects model (I 2=0%, Pheterogeneity=0.8081).

Figure 4 Odds ratios of diarrhea associated with sitagliptin versus controls.

Abbreviations: OR, odds ratio; CI, confidence interval; W, weight.
Figure 4 Odds ratios of diarrhea associated with sitagliptin versus controls.

Publication bias

We observed no significant evidence of publication bias for the OR of diarrhea events in this analysis by a funnel plot (), Egger’s test (P=0.991>0.05, 95% CI: −1.64, 1.62), or Begg’s test (Z=0<1.96, P=1.0>0.05).

Figure 5 Funnel plot of standard error by odds ratio for diarrhea.

Figure 5 Funnel plot of standard error by odds ratio for diarrhea.

Discussion

Diarrhea associated with sitagliptin is an important issue in patients receiving medication. However, due to the high background incidence of diarrhea, it may be very difficult to distinguish between spontaneous and actual drug-related diarrhea events in T2DM patients. Wu et alCitation46 found that, compared with controls, DPP-4 inhibitor monotherapy, which included sitagliptin, was associated with a lower risk of gastrointestinal (GI) adverse events involving diarrhea (relative risk =0.63, 95% CI: [0.55–0.70], P<0.00001). So far, no studies have explored the association between diarrhea and sitagliptin. Therefore, we have conducted this study to determine the overall incidence and risk of diarrhea in T2DM patients treated with sitagliptin.

Sitagliptin as a novel T2DM therapy improves alpha islet function due to the increased concentrations of active GLP-1, which stimulates insulin secretion and inhibits glucagon secretion.Citation47 In one study,Citation48 sitagliptin (100 mg) reduced HbA1c by 0.6% from a baseline of 7.7% in 555 subjects. Another study,Citation49 comprising 743 subjects, reported that sitagliptin reduced HbA1c by 0.8% from a baseline of 7.8%. The improved hyperglycemia during sitagliptin monotherapy was sustained over at least 2 years, as shown in a 52-week study of an open-label extension.Citation21 Sitagliptin at 100 mg reduced HbA1c by 0.7% from a baseline of 7.5%. A placebo-controlled, multicenter studyCitation37 showed that sitagliptin at 100 mg or 200 mg once daily reduced HbA1c by 0.6% and 0.5%, respectively, from a baseline of 8.1%. All of these studies have shown that sitagliptin has a positive clinical effect in reducing glycemia as a monotherapy. However, the etiology and pathophysiology of sitagliptin-related diarrhea are largely unknown.

In our study, we strictly defined inclusion criteria to collect the RCTs of T2DM patients treated with sitagliptin. This method of meta-analysis could increase clinical samples and improve productivity based on statistics, and we were able to obtain a more accurate conclusion to choose a suitable therapeutic scheme in clinical practice.

In our study, 8,891 patients from 30 RCTs demonstrated that the pooled incidence of sitagliptin-associated diarrhea was 4.48% (95% CI: 3.59%–5.58%). According to a subgroup analysis, we found that the incidence of diarrhea was related to the duration and dosage of sitagliptin treatment. If the dosage of sitagliptin was ≥100 mg, the incidence of diarrhea with treatment times <30 weeks (3.83%, 95% CI: 3.02%–4.84%) was lower than that with treatment times >30 weeks (5.41%, 95% CI: 3.62%–8.01%).

Of note, we also found no differences in diarrhea risk between sitagliptin and placebo therapies (OR=1.10, 95% CI: 0.78–1.55, P=0.58; ). Sitagliptin did not increase the risk of diarrhea in patients with T2DM. One possible explanation for this finding is that diarrhea is due to the T2DM itself. As we know, GI disorders are a common complication of T2DM, including abdominal distension, diarrhea, and constipation. One studyCitation50 reports that the frequency of diarrhea is 5.3% in T2DM patients. Moreover, a large population survey asking participants about GI-related disordersCitation51 indicated that the OR was 2.06 in diabetic patients compared with controls, and the prevalence of diarrhea was 15.6%. Histological evidence of sympathetic and parasympathetic nerve impairment has been observed in T2DM patients.Citation52 Sympathetic and parasympathetic nerves regulate the movement of the small intestine, and the damaged nerve tracts could impair GI motility. Previous studies have shown similar results with sympathetic nerve selective deletion in the islets of diabetic rats.Citation53 Based on the autonomic nerve changes in T2DM, the risk of diarrhea may easily increase in T2DM patients compared with normal people. Another possible explanation for this finding is the underreporting of diarrhea; in fact, diarrhea as an independent adverse event reported in trials is low. In our research, 30.2% of RCTs were excluded because data on diarrhea were unavailable. Additionally, only 14 RCTs were included in our study to investigate the risk of diarrhea associated with sitagliptin. Thus, the power to investigate the risk is small. Nevertheless, because sitagliptin is increasingly used in routine treatment of T2DM patients and in clinical trials with other agents, endocrinologist and primary care physicians should be aware of the incidence and risk of diarrhea associated with sitagliptin. Furthermore, physicians should monitor and treat this disorder appropriately.

Heterogeneity is a potential confounding factor that can influence the results of all meta-analyses. In the present study, we did not observe a significant heterogeneity in the meta-analysis. However, some limitations did exist. First, the RCTs were performed at various international institutions by different investigators and may have some potential bias in reporting the types of adverse events. In particular, the frequency of diarrhea is underreported in clinical trials independently. Second, the results are from patients at a follow-up time and thus may not be fully reflective of general patients, nor of a more prolonged use. Third, although diarrhea data are prospectively collected in individual studies, there are potentially important differences among the studies, including race, dosage and administration schedules of sitagliptin, duration of the study, and investigators. All of these increase the clinical heterogeneity among included trials. Additionally, our study includes a mixed population of patients treated with sitagliptin-based combination therapy or sitagliptin monotherapy. Therefore, the design of treatment is not the same in all arms, and this might be another source of heterogeneity.

Despite these limitations, the present meta-analysis provides some clinical reference for the treatment of diabetic diarrhea. In the treatment of diabetic diarrhea, it is important to identify the influence of medicine. Metformin, which belongs to the biguanide class of drugs, is the first-line OHA for the treatment of T2DM, and has been shown to reduce the rate of glucose production through reductions in hepatic gluconeogenesis.Citation54,Citation55 However, treatment with metformin is generally associated with a high incidence of adverse GI effects, including diarrhea, nausea, and vomiting.Citation56Citation58 Diarrhea is the most commonly reported symptom of adverse GI effects, and metformin can lead to malabsorptive diarrhea ranging from 10% to 53% in T2DM patients.Citation59 Furthermore, in 5% of T2DM cases, diarrhea led to the discontinuation of metformin use.Citation60 Our results indicate that sitagliptin did not increase the risk of diabetic diarrhea. The pooled OR of sitagliptin compared with a placebo was 1.10 (95% CI: 0.78–1.55, P=0.58; ). Sitagliptin is not a potential diarrhea-inducing medicine. If diabetic diarrhea occurred, sitagliptin may be a better choice compared with metformin in T2DM patients.

Conclusion

In conclusion, our study has shown that there is no difference in diarrhea risk between sitagliptin and controlled therapies. Furthermore, sitagliptin is not a medicine that potentially increases the risk of diabetic diarrhea. Further studies are still recommended to investigate this association.

Acknowledgments

This work was supported by the Zhejiang TCM KEY research fund projects (number 2013ZZ009), Zhejiang TCM research fund projects (number 2013ZA078), and Zhejiang Provincial Education Department Research Fund Project (number Y201225107).

Supplementary materials

Figure S1 Embase search strategy.

Abbreviation: exp, extensive search.
Figure S1 Embase search strategy.

Figure S2 PubMed search strategy.

Figure S2 PubMed search strategy.
Figure S2 PubMed search strategy.

Figure S3 Cochrane Library search strategy.

Abbreviations: ab, abstract; kw, keyword; ti, title.
Figure S3 Cochrane Library search strategy.

Table S1 PRISMA 2009 checklist

Reference

  • Moher D Liberati A Tetzlaff J Altman DG the PRISMA Group Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement Plos Med 2009 6 7 e1000097 19621072

Disclosure

There are no financial/commercial conflicts of interest involving any of the authors of this study.

References

  • Wild S Roglic G Green A Sicree R King H Global prevalence of diabetes: estimates for the year 2000 and projections for 2030 Diabetes Care 2004 27 5 1047 1053 15111519
  • Ren CJ Zhang Y Cui WZ Mu ZM Progress in the role of oxidative stress in the pathogenesis of type 2 diabetes Sheng Li Xue Bao 2013 65 6 664 673 Chinese 24343725
  • Bogaert YE Schrier RW Into the future: prevention of diabetes Contrib Nephrol 2011 170 256 263 21659778
  • Zenari L Marangoni A What are the preferred strategies for control of glycaemic variability in patients with type 2 diabetes mellitus? Diabetes Obes Metab 2013 15 Suppl 2 17 25 24034516
  • McGill JB Pharmacotherapy in type 2 diabetes: a functional schema for drug classification Curr Diabetes Rev 2012 8 4 257 267 22515702
  • Gallwitz B Sitagliptin: Profile of a novel DPP-4 inhibitor for the treatment of type 2 diabetes Drugs Today (Barc) 2007 43 1 13 25 17315049
  • Omar B Ahren B Pleiotropic mechanisms for the glucose-lowering action of DPP-4 inhibitors Diabetes 2014 63 7 2196 2202 24962916
  • Gallwitz B Therapies for the treatment of type 2 diabetes mellitus based on incretin action Minerva Endocrinol 2006 31 2 133 147 16682937
  • Aschner P Kipnes MS Lunceford JK Effect of the dipeptidyl peptidase-4 inhibitor sitagliptin as monotherapy on glycemic control in patients with type 2 diabetes Diabetes Care 2006 29 12 2632 2637 17130196
  • Russell-Jones D Cuddihy RM Hanefeld M Efficacy and safety of exenatide once weekly versus metformin, pioglitazone, and sitagliptin used as monotherapy in drug-naive patients with type 2 diabetes (DURATION-4): a 26-week double-blind study Diabetes Care 2012 35 2 252 258 22210563
  • Begg CB Mazumdar M Operating characteristics of a rank correlation test for publication bias Biometrics 1994 50 4 1088 1101 7786990
  • American Diabetes Association Standards of medical care in diabetes-2014 Diabetes Care 2014 37 Suppl 1 S14 S80 24357209
  • World Health Organization Definition, Diagnosis, and Classification of Diabetes Mellitus and its Complications: report of a WHO consultation Geneva World Health Organization 1999 Available from: http://whqlibdoc.who.int/hq/1999/who_ncd_ncs_99.2.pdf Accessed October 3, 2014
  • Jadad AR Moore RA Carroll D Assessing the quality of reports of randomized clinical trials: is blinding necessary? Control Clin Trials 1996 17 1 1 12 8721797
  • Sweeting MJ Sutton AJ Lambert PC What to add to nothing? Use and avoidance of continuity corrections in meta-analysis of sparse data Stat Med 2004 23 9 1351 1375 15116347
  • Zintzaras E Ioannidis JP Heterogeneity testing in meta-analysis of genome searches Genet Epidemiol 2005 28 2 123 137 15593093
  • Egger M Davey Smith G Schneider M Minder C Bias in meta-analysis detected by a simple, graphical test BMJ 1997 315 7109 629 634 9310563
  • Maindonald J Braun WJ Data Analysis and Graphics Using R: An Example-Based Approach 3rd ed New York Cambridge University Press 2010
  • Charbonnel B Karasik A Liu J Wu M Meininger G Sitagliptin Study 020 Group Efficacy and safety of the dipeptidyl peptidase-4 inhibitor sitagliptin added to ongoing metformin therapy in patients with type 2 diabetes inadequately controlled with metformin alone Diabetes Care 2006 29 12 2638 2643 17130197
  • Chan JCN Scott R Arjona Ferreira JC Safety and efficacy of sitagliptin in patients with type 2 diabetes and chronic renal insufficiency Diabetes Obes Metab 2008 10 7 545 555 18518892
  • Williams-Herman D Johnson J Teng R Efficacy and safety of initial combination therapy with sitagliptin and metformin in patients with type 2 diabetes: a 54-week study Curr Med Res Opin 2009 25 3 569 583 19232032
  • Williams-Herman D Johnson J Teng R Efficacy and safety of sitagliptin and metformin as initial combination therapy and as monotherapy over 2 years in patients with type 2 diabetes Diabetes Obes Metab 2010 12 5 442 451 20415693
  • Bergenstal RM Forti A Chiasson J-L Woloschak M Boldrin M Balena R Efficacy and safety of taspoglutide versus sitagliptin for type 2 diabetes mellitus (T-emerge 4 trial) Diabetes Ther 2012 3 1 13 23138449
  • Dobs AS Goldstein BJ Aschner P Efficacy and safety of sitagliptin added to ongoing metformin and rosiglitazone combination therapy in a randomized placebo-controlled 54-week trial in patients with type 2 diabetes J Diabetes 2013 5 1 68 79 22742523
  • Schernthaner G Gross JL Rosenstock J Canagliflozin compared with sitagliptin for patients with type 2 diabetes who do not have adequate glycemic control with metformin plus sulfonylurea: a 52-week randomized trial Diabetes Care 2013 36 9 2508 2515 23564919
  • Rosenstock J Brazg R Andryuk PJ Lu K Stein P Sitagliptin Study 019 Group Efficacy and safety of the dipeptidyl peptidase-4 inhibitor sitagliptin added to ongoing pioglitazone therapy in patients with type 2 diabetes: a 24-week, multicenter, randomized, double-blind, placebo-controlled, parallel-group study Clin Ther 2006 28 10 1556 1568 17157112
  • Goldstein BJ Feinglos MN Lunceford JK Johnson J Williams-Herman DE Sitagliptin 036 Study Group Effect of initial combination therapy with sitagliptin, a dipeptidyl peptidase-4 inhibitor, and metformin on glycemic control in patients with type 2 diabetes Diabetes Care 2007 30 8 1979 1987 17485570
  • Scott R Wu M Sanchez M Stein P Efficacy and tolerability of the dipeptidyl peptidase-4 inhibitor sitagliptin as monotherapy over 12 weeks in patients with type 2 diabetes Int J Clin Pract 2007 61 1 171 180 17156104
  • Raz I Chen Y Wu M Efficacy and safety of sitagliptin added to ongoing metformin therapy in patients with type 2 diabetes Curr Med Res Opin 2008 24 2 537 550 18194595
  • Aschner P Katzeff HL Guo H Efficacy and safety of monotherapy of sitagliptin compared with metformin in patients with type 2 diabetes Diabetes Obes Metab 2010 12 3 252 261 20070351
  • Bergenstal RM Wysham C Macconell L Efficacy and safety of exenatide once weekly versus sitagliptin or pioglitazone as an adjunct to metformin for treatment of type 2 diabetes (DURATION-2): a randomised trial Lancet 2010 376 9739 431 439 20580422
  • Barzilai N Guo H Mahoney EM Efficacy and tolerability of sitagliptin monotherapy in elderly patients with type 2 diabetes: a randomized, double-blind, placebo-controlled trial Curr Med Res Opin 2011 27 5 1049 1058 21428727
  • Aschner P Chan J Owens DR Insulin glargine versus sitagliptin in insulin-naive patients with type 2 diabetes mellitus uncontrolled on metformin (EASIE): a multicentre, randomised open-label trial Lancet 2012 379 9833 2262 2269 22683131
  • Yang W Guan Y Shentu Y The addition of sitagliptin to ongoing metformin therapy significantly improves glycemic control in Chinese patients with type 2 diabetes J Diabetes 2012 4 3 227 237 22672586
  • Arjona Ferreira JC Corry D Mogensen CE Efficacy and safety of sitagliptin in patients with type 2 diabetes and ESRD receiving dialysis: a 54-week randomized trial Am J Kidney Dis 2013 61 4 579 587 23352379
  • Arjona Ferreira JC Marre M Barzilai N Efficacy and safety of sitagliptin versus glipizide in patients with type 2 diabetes and moderate-to-severe chronic renal insufficiency Diabetes Care 2013 36 5 1067 1073 23248197
  • Raz I Hanefeld M Xu L Efficacy and safety of the dipeptidyl peptidase-4 inhibitor sitagliptin as monotherapy in patients with type 2 diabetes mellitus Diabetologia 2006 49 11 2564 2571 17001471
  • Hermansen K Kipnes M Luo E Efficacy and safety of the dipeptidyl peptidase-4 inhibitor, sitagliptin, in patients with type 2 diabetes mellitus inadequately controlled on glimepiride alone or on glimepiride and metformin Diabetes Obes Metab 2007 9 5 733 745 17593236
  • Mohan V Yang W Son H-Y Efficacy and safety of sitagliptin in the treatment of patients with type 2 diabetes in China, India, and Korea Diabetes Res Clin Pract 2009 83 1 106 116 19097665
  • Chien M-N Lee C-C Chen W-C Liu S-C Leung C-H Wang C-H Effect of sitagliptin as add-on therapy in elderly type 2 diabetes patients with inadequate glycemic control in Taiwan Int J Gerontol 2011 5 2 103 106
  • Pratley R Nauck M Bailey T One year of liraglutide treatment offers sustained and more effective glycaemic control and weight reduction compared with sitagliptin, both in combination with metformin, in patients with type 2 diabetes: a randomised, parallel-group, open-label trial Int J Clin Pract 2011 65 4 397 407 21355967
  • Rosenstock J Aggarwal N Polidori D Dose-ranging effects of canagliflozin, a sodium-glucose cotransporter 2 inhibitor, as add-on to metformin in subjects with type 2 diabetes Diabetes Care 2012 35 6 1232 1238 22492586
  • Kobayashi K Yokoh H Sato Y Efficacy and safety of the dipeptidyl peptidase-4 inhibitor sitagliptin compared with α-glucosidase inhibitor in Japanese patients with type 2 diabetes inadequately controlled on sulfonylurea alone (SUCCESS-2): a multicenter, randomized, open-label, non-inferiority trial Diabetes Obes Metab 2014 16 8 761 765 24447683
  • Moher D Liberati A Tetzlaff J Altman DG Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement Int J Surg 2010 8 5 336 341 20171303
  • Scott R Loeys T Davies MJ Efficacy and safety of sitagliptin when added to ongoing metformin therapy in patients with type 2 diabetes Diabetes Obes Metab 2008 10 10 959 969 18201203
  • Wu D Li L Liu C Efficacy and safety of dipeptidyl peptidase-4 inhibitors and metformin as initial combination therapy and as monotherapy in patients with type 2 diabetes mellitus: a meta-analysis Diabetes Obes Metab 2014 16 1 30 37 23803146
  • Argyrakopoulou G Doupis J DPP4 inhibitors: from sitagliptin monotherapy to the new alogliptin-pioglitazone combination therapy Adv Ther 2009 26 3 272 280 19259628
  • Hanefeld M Herman GA Wu M Once-daily sitagliptin, a dipeptidyl peptidase-4 inhibitor, for the treatment of patients with type 2 diabetes Curr Med Res Opin 2007 23 6 1329 1339 17559733
  • Scott R Wu M Sanchez M Stein P Efficacy and tolerability of the dipeptidyl peptidase-4 inhibitor sitagliptin as monotherapy over 12 weeks in patients with type 2 diabetes Int J Clin Pract 2007 61 1 171 180 17156104
  • Oh JH Choi MG Kang MI The prevalence of gastrointestinal symptoms in patients with non-insulin dependent diabetes mellitus Korean J Intern Med 2009 24 4 309 317 19949728
  • Bytzer P Talley NJ Leemon M Young LJ Jones MP Horowitz M Prevalence of gastrointestinal symptoms associated with diabetes mellitus: a population-based survey of 15,000 adults Arch Intern Med 2001 161 16 1989 1996 11525701
  • Nakamura T Suda T Kon M Pathophysiology and treatment of diabetic diarrhea J Smooth Muscle Res 1996 32 2 27 42 8845564
  • Mei Q Mundinger TO Lernmark A Taborsky GJ Early, selective, and marked loss of sympathetic nerves from the islets of biobreeder diabetic rats Diabetes 2002 51 10 2997 3002 12351439
  • Johnson AB Webster JM Sum CF The impact of metformin therapy on hepatic glucose production and skeletal muscle glycogen synthase activity in overweight type II diabetic patients Metabolism 1993 42 9 1217 1222 8412779
  • Perriello G Misericordia P Volpi E Acute antihyperglycemic mechanisms of metformin in NIDDM. Evidence for suppression of lipid oxidation and hepatic glucose production Diabetes 1994 43 7 920 928 8013758
  • Jabbour S Ziring B Advantages of extended-release metformin in patients with type 2 diabetes mellitus Postgrad Med 2011 123 1 15 23 21293080
  • Zolk O Disposition of metformin: variability due to polymorphisms of organic cation transporters Ann Med 2012 44 2 119 129 21366511
  • Padwal RS Gabr RQ Sharma AM Effect of gastric bypass surgery on the absorption and bioavailability of metformin Diabetes Care 2011 34 6 1295 1300 21478461
  • Gould M Sellin JH Diabetic diarrhea Curr Gastroenterol Rep 2009 11 5 354 359 19765362
  • Bouchoucha M Uzzan B Cohen R Metformin and digestive disorders Diabetes Metab 2011 37 2 90 96 21236717
  • Lavalle-Gonzalez FJ Januszewicz A Davidson J Efficacy and safety of canagliflozin compared with placebo and sitagliptin in patients with type 2 diabetes on background metformin monotherapy: a randomised trial Diabetologia 2013 56 12 2582 2592 24026211
  • Merck Sharp & Dohme Corp Safety and Efficacy of Co-Administration of Sitagliptin and Metformin in China (MK-0431-121) Available from: http://www.clinicaltrials.gov/ct2/show/NCT01076088?term=NCT01076088&rank=1. NLM identifier: NCT 01076088 Accessed October 23, 2014
  • Merck Sharp & Dohme Corp A Study of Sitagliptin in Patients With Type 2 Diabetes Mellitus Who Have Inadequate Glycemic Control on Diet/Exercise Therapy (0431-054) Available from: http://www.clinicaltrials.gov/ct2/show/NCT00411554?term=00411554&rank=1. NLM identifier: NCT 00411554 Accessed October 23, 2014
  • Merck Sharp & Dohme Corp An Investigational Drug Study in Patients With Type 2 Diabetes Mellitus (0431-024) Available from: http://www.clinicaltrials.gov/ct2/show/NCT00094770?term=NCT00094770&rank=1. NLM identifier: NCT 00094770 Accessed October 23, 2014